A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05% Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis

Trial Profile

A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05% Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2013

At a glance

  • Drugs Malathion (Primary) ; Permethrin
  • Indications Pediculosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 31 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top